{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:20:29Z","timestamp":1787624429842,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Palivizumab is an FDA-approved monoclonal antibody for preventing severe respiratory syncytial virus (RSV) infections in high-risk children. However, its real-world safety profile, particularly beyond clinical trial populations, remains incompletely characterized. This study aimed to systematically analyze adverse events (AEs) associated with palivizumab using two decades of data from the FDA Adverse Event Reporting System (FAERS) to identify known, novel, and rare safety signals. This study aimed to characterize the post-marketing safety profile of palivizumab and identify AE signals using 20\u00a0years of FDA Adverse Event Reporting System (FAERS) data. A retrospective pharmacovigilance study was conducted using FAERS data from Q1 2004 to Q2 2024. Duplicate reports were removed, and palivizumab-related AE reports (primary suspected drug) were extracted. AEs were standardized via MedDRA v27.0 and categorized by system organ classes (SOCs) and preferred terms (PTs). Disproportionality analyses, including reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN), were used to detect signals, with predefined criteria for signal validation. Among 21,558,936 total FAERS reports, 14,120 (0.065%) palivizumab-related AE cases were included, predominantly in infants aged 28\u00a0days\u201323\u00a0months (45.92% of all cases); 51.74% of cases with known sex were male. The most frequent serious outcome was hospitalization (60.98%), followed by death (12.12%). Three system organ class\u2013level positive signals were identified, including two novel signals (Infections and infestations; Congenital, familial and genetic disorders). The strongest preferred term\u2013level positive signals were RSV-related events, with novel signals including infantile spitting up, post-tussive vomiting, oligodipsia, and Kawasaki\u2019s disease. This 20-year real-world study confirms known AEs of palivizumab and identifies novel signals, particularly in infection-related and congenital disorder categories. These findings do not establish causality but highlight the need for prospective studies to validate associations, guiding safer clinical use in high-risk pediatric populations.<\/jats:p>","DOI":"10.1007\/s00210-026-05485-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:36:00Z","timestamp":1780558560000},"page":"17945-17957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"399","author":[{"given":"Qing","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"5485_CR1","doi-asserted-by":"crossref","unstructured":"Alenzi KA, Alsuhaibani D, Batarfi B, Alshammari TM (2024) Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol 15:1364110","DOI":"10.3389\/fphar.2024.1364110"},{"issue":"6","key":"5485_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/irv.12729","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Buda S, Schuler E et al (2020) Risk factors for hospitalized Respiratory Syncytial Virus disease and its severe outcomes. Influenza Other Respir Viruses 14(6):658\u2013670","journal-title":"Influenza Other Respir Viruses"},{"key":"5485_CR3","doi-asserted-by":"crossref","unstructured":"Caserta MT, O'Leary ST, Munoz FM et al (2023) Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 152(1):e2023061803","DOI":"10.1542\/peds.2023-061803"},{"issue":"6","key":"5485_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00151829-200605060-00011","volume":"5","author":"S Chavez-Bueno","year":"2006","unstructured":"Chavez-Bueno S, Mejias A, Welliver RC (2006) Respiratory Syncytial Virus bronchiolitis: current and future strategies for treatment and prophylaxis. Treat Respir Med 5(6):483\u2013494","journal-title":"Treat Respir Med"},{"key":"5485_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-021-00520-y","author":"D Dubrall","year":"2021","unstructured":"Dubrall D, Leitzen S, Toni I et al (2021) Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. BMC Pharmacol Toxicol. https:\/\/doi.org\/10.1186\/s40360-021-00520-y","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"5485_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532\u2013540","journal-title":"J Pediatr"},{"issue":"3","key":"5485_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00148581-200406030-00004","volume":"6","author":"C Fenton","year":"2004","unstructured":"Fenton C, Scott LJ, Plosker GL (2004) Palivizumab. Paediatr Drugs 6(3):177\u2013197","journal-title":"Paediatr Drugs"},{"issue":"10","key":"5485_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","volume":"46","author":"V Giunchi","year":"2023","unstructured":"Giunchi V, Fusaroli M, Hauben M et al (2023) Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach. Drug Saf 46(10):921\u2013926","journal-title":"Drug Saf"},{"issue":"7","key":"5485_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10096-003-0961-z","volume":"22","author":"JR Groothuis","year":"2003","unstructured":"Groothuis JR (2003) Safety of palivizumab in preterm infants 29 to 32 weeks\u2019 gestational age without chronic lung disease to prevent serious Respiratory Syncytial Virus infection. Eur J Clin Microbiol Infect Dis 22(7):414\u2013417","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"5485_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"Group TI-RS","year":"1998","unstructured":"Group TI-RS (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3):531\u2013537","journal-title":"Pediatrics"},{"issue":"3","key":"5485_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/infdis\/161.3.402","volume":"161","author":"CA Heilman","year":"1990","unstructured":"Heilman CA (1990) From the National Institute of Allergy and Infectious Diseases and the World Health Organization: respiratory syncytial and parainfluenza viruses. J Infect Dis 161(3):402\u2013406","journal-title":"J Infect Dis"},{"issue":"5","key":"5485_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","volume":"176","author":"S Johnson","year":"1997","unstructured":"Johnson S, Oliver C, Prince GA et al (1997) Development of a humanized monoclonal antibody (MEDI\u2010493) with potent in vitro and in vivo activity against Respiratory Syncytial Virus. J Infect Dis 176(5):1215\u20131224","journal-title":"J Infect Dis"},{"issue":"3","key":"5485_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ppul.10175","volume":"34","author":"T Lacaze\u2010Masmonteil","year":"2002","unstructured":"Lacaze\u2010Masmonteil T, Roz\u00e9 JC, Fauroux B (2002) Incidence of Respiratory Syncytial Virus\u2010related hospitalizations in high\u2010risk children: follow\u2010up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol 34(3):181\u2013188","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"5485_CR14","first-page":"191","volume":"1","author":"L Liu","year":"2019","unstructured":"Liu L, Dong B, Guo D (2019) Study on the relationship between Respiratory Syncytial Virus infection and bronchial asthma. Contemp Med 1(2):191\u2013194","journal-title":"Contemp Med"},{"key":"5485_CR15","doi-asserted-by":"crossref","unstructured":"Liu W, Du Q, Guo Z et al (2023) Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Front Pharmacol 14:1283247","DOI":"10.3389\/fphar.2023.1283247"},{"key":"5485_CR16","doi-asserted-by":"crossref","unstructured":"Mazur NI, L\u00f6wensteyn YN, Terstappen J et al (2023) Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1\/2b randomized placebo-controlled trial. eClinicalMedicine 66:102324","DOI":"10.1016\/j.eclinm.2023.102324"},{"key":"5485_CR17","doi-asserted-by":"crossref","unstructured":"Messina A, Germano C, Avellis V et al (2022) New strategies for the prevention of respiratory syncytial virus (RSV). Early Human Dev 174:105666","DOI":"10.1016\/j.earlhumdev.2022.105666"},{"key":"5485_CR18","doi-asserted-by":"publisher","unstructured":"Mori M, Yoshizaki K, Watabe S et al (2023) Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial. Lancet Reg Health West Pac 39:100847.\u00a0https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100847","DOI":"10.1016\/j.lanwpc.2023.100847"},{"issue":"9725","key":"5485_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD et al (2010) Global burden of acute lower respiratory infections due to Respiratory Syncytial Virus in young children: a systematic review and meta-analysis. Lancet 375(9725):1545\u20131555","journal-title":"Lancet"},{"issue":"9","key":"5485_CR20","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","volume":"13","author":"B Resch","year":"2017","unstructured":"Resch B (2017) Product review on the monoclonal antibody palivizumab for prevention of Respiratory Syncytial Virus infection. Hum Vaccin Immunother 13(9):2138\u20132149","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"5485_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5485_CR22","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.05.020416","author":"T Shi","year":"2015","unstructured":"Shi T, Balsells E, Wastnedge E et al (2015) Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta\u2013analysis. J Glob Health. https:\/\/doi.org\/10.7189\/jogh.05.020416","journal-title":"J Glob Health"},{"key":"5485_CR23","doi-asserted-by":"crossref","unstructured":"Shi T, McAllister DA, O\u2019Brien KL et al (2017) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390(10098):946\u2013958","DOI":"10.1016\/S0140-6736(17)30938-8"},{"key":"5485_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.621","author":"Y Yao","year":"2024","unstructured":"Yao Y, Yang Y, Ji M et al (2024) Airway epithelial\u2010derived exosomes induce acute asthma exacerbation after Respiratory Syncytial Virus infection. MedComm. https:\/\/doi.org\/10.1002\/mco2.621","journal-title":"MedComm"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05485-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:24:19Z","timestamp":1787621059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5485"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05485-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}